SEOUL -- Samsung Biologics has become South Korea's third-most-valuable company, besting the much larger Hyundai Motor thanks to its status as a rare winner in the coronavirus economy.
Pharmaceuticals
Samsung Biologics bumps Hyundai from Korean market's top 3
Drugmaker's market cap surges to $31bn on lucrative virus treatment deal
